Meditopes and meditope-binding antibodies and uses thereof

1. A complex comprising:

a meditope-enabled antibody or antigen-binding fragment thereof, wherein said meditope-enabled antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region; a heavy chain constant region (CH) or portion thereof; a light chain variable (VL) region comprising a threonine at position 40, an asparagine at position 41, an isoleucine or valine at position 83, and an aspartate at position 85, according to Kabat numbering; and a light chain constant region (CL) or portion thereof; wherein the meditope-enabled antibody or antigen-binding fragment thereof comprises a meditope-binding site which (i) comprises threonine, asparagine and aspartate at residues 40, 41 and 85, respectively, and isoleucine or valine at residue 83 of the VL of the meditope-enabled antibody or antigen-binding fragment thereof, and glutamine, isoleucine, glutamine at residues 39, 89, and 105, respectively, and leucine or serine at residue 108 of the VH of the meditope-enabled antibody or antigen-binding fragment thereof, both according to Kabat numbering and (ii) can bind to a peptide comprising the amino acid sequence of SEQ ID NO: 1 or 2;

a meditope bound to the meditope-binding site; and

a chemotherapeutic agent conjugated to the meditope,

wherein the meditope comprises a peptide of: C-QFDLSTRRLK-C(SEQ ID NO: 1),

wherein:

the meditope-enabled antibody or antigen-binding fragment thereof does not specifically bind to the epitope of an EGFR that is specifically bound by cetuximab.

2. The complex of claim 1 , wherein the peptide in (ii) is cyclic.

3. The complex of claim 2 , wherein the peptide is cyclized by disulfide bridge, a thioether bridge, a lactam linkage, or cycloaddition.

4. The complex of claim 1 , wherein the chemotherapeutic agent is a cytotoxic drug.

5. The complex of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of an alkylating agent, an antimetabolite, an anti-tumor antibiotic, a topoisomerase inhibitor, a mitotic inhibitor and an immunotherapeutic.

6. The complex of claim 1 , wherein the chemotherapeutic is selected from the group consisting of 13-cis-retinoic acid, 2-chlorodeoxyadenosine, 5-azacitidine, 5-fluorouracil, 6-mercaptopurine, 6-thioguanine, actinomycin-D, adriamycin, alitretinoin, all-transretinoic acid, altretamine, amethopterin, amifostine, anagrelide, anastrozole, arabinosylcytosine, arsenic trioxide, amsacrine, aminocamptothecin, aminoglutethimide, azacytidine, bendamustine, bexarotene, bicalutamide, bortezomib, bleomycin, busulfan, calcium leucovorin, citrovorum factor, capecitabine, canertinib, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cortisone, cyclophosphamide, cytarabine, darbepoetin alfa, dasatinib, daunomycin, decitabine, denileukin diftitox, dexamethasone, dexasone, dexrazoxane, dactinomycin, decarbazine, docetaxel, doxorubicin, doxifluridine, eniluracil, epirubicin, erlotinib, everolimus, exemestane, estramustine, etoposide, fluoxymesterone, fulvestrant, flavopiridol, floxuridine, fludarabine, fluorouracil, flutamide, gefitinib, gemcitabine, goserelin, hexamethylmelamine, hydrocortisone hydroxyurea, isotretinoin, ixabepilone, idarubicin, imatinib mesylate, ifosfamide, irinotecan, lapatinib, lenalidomide, letrozole, leucovorin, leuprolide, lomustine, mechlorethamine, megestrol, melphalan, mercaptopurine, mesna, methotrexate, methylprednisolone, mitomycin C, mitotane, mitoxantrone, nelarabine, nilutamide, octreotide, oprelvekin, oxaliplatin, paclitaxel, pamidronate, pemetrexed, pentostatin, plicamycin, prednisolone, prednisone, procarbazine, raloxifene, romiplostim, ralitrexed, sapacitabine, sargramostim, satraplatin, sorafenib, sunitinib, semustine, streptozocin, tamoxifen, tegafur, tegafur-uracil, temsirolimus, temozolamide, teniposide, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tretinoin, trimitrexate, alrubicin, vincristine, vinblastine, vindestine, vinorelbine, vorinostat, and zoledronic acid.

7. The complex of claim 2 , wherein the peptide is cyclized by disulfide bridge.